The purpose of the Biostatistics Core is to collaborate with SPORE investigators on their research projects and to monitor the conduct of the clinical trials. Specifically, the Biostatistics Core will develop statistical designs, develop statistical analysis plans, perform data acquisition, develop databases, archive data, develop clinical research forms, perform data monitoring for clinical trials involving human subjects, perform data analysis and interpretation and aid in the development of manuscripts, abstracts and presentations. This purpose will be accomplished through the following specific aims: 1) Collaborate with SPORE investigators on study design to develop projects with appropriate statistical operating characteristics 2) Provide a statistical analysis plan for each SPORE project 3) Perform statistical analyses of project results as specified in the statistical analysis plan and collaborate with SPORE investigators on the interpretation and reporting of research findings 4) Monitor the conduct of SPORE clinical research projects to ensure patient safety and the scientific integrity of the projects 5) Collaborate with SPORE investigators on interpretation of data analysis results and aid in the development of manuscripts, abstracts and presentations. A team of two faculty and two Masters-trained biostatisticians has been assembled to meet the range of statistical methodological and analytical needs of the projects, including expertise in design and analysis of high-dimensional data and clinical trials. This team will ensure that the design and analyses are appropriate to meet the aims of the projects, which is essential to the success of the SPORE. The Biostatistics Core will be directed by Jane Meza Ph.D. and additionally staffed by Fang Yu Ph.D. (specializing in high-dimensional data analysis), Lynette Smith M.S. (Masters-trained biostatistician specializing in high-dimensional data analysis) and Robin High M.A. (Masters-trained biostatistician).
Biostatistical and computing expertise is essential to the design of laboratory-based and clinical studies because it ensures the efficient use of financial, animal and patient resources while minimizing the likelihood of false conclusions. The projects of this SPORE will generate complex data that will require substantial biostatistical and computing input to be effectively analyzed and presented.
| Wang, Gang; Biswas, Anup K; Ma, Wanchao et al. (2018) Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat Med 24:770-781 |
| Murthy, Divya; Attri, Kuldeep S; Singh, Pankaj K (2018) Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Front Physiol 9:335 |
| Barkeer, Srikanth; Chugh, Seema; Karmakar, Saswati et al. (2018) Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. BMC Cancer 18:1157 |
| Rana, Sandeep; Sonawane, Yogesh A; Taylor, Margaret A et al. (2018) Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorg Med Chem Lett 28:3736-3740 |
| Roy, Sohini; Bag, Arup K; Dutta, Samikshan et al. (2018) Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions. Cancer Res 78:5600-5617 |
| Hall, Bradley R; Cannon, Andrew; Atri, Pranita et al. (2018) Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Oncotarget 9:19396-19405 |
| Banerjee, Kasturi; Kumar, Sushil; Ross, Kathleen A et al. (2018) Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett 417:35-46 |
| Wiest, Edwin J; Smith, Heather Jensen; Hollingsworth, Michael A (2018) Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum. Biochem Biophys Res Commun 501:858-862 |
| Chugh, Seema; Barkeer, Srikanth; Rachagani, Satyanarayana et al. (2018) Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice. Gastroenterology 155:1608-1624 |
| Jahan, Rahat; Macha, Muzafar A; Rachagani, Satyanarayana et al. (2018) Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-?1/FAK/ERK pathway. Biochim Biophys Acta Mol Basis Dis 1864:2538-2549 |
Showing the most recent 10 out of 191 publications
